Literature DB >> 15794935

Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design.

Walter Jantschko1, Paul Georg Furtmüller, Martina Zederbauer, Karin Neugschwandtner, Isabella Lehner, Christa Jakopitsch, Jürgen Arnhold, Christian Obinger.   

Abstract

Myeloperoxidase plays a fundamental role in oxidant production by neutrophils. It uses hydrogen peroxide and chloride to catalyze the production of hypochlorous acid (HOCl), which contributes to both bacterial killing and oxidative injury of host tissue. Thus, MPO is an interesting target for anti-inflammatory therapy. Here, based on the extraordinary and MPO-specific redox properties of its intermediates compound I and compound II, we present a rational approach in selection and design of reversible inhibitors of HOCl production mediated by MPO. In detail, indole and tryptamine derivatives were investigated for their ability to reduce compounds I and II and to affect the chlorinating activity of MPO. It is shown that these aromatic one-electron donors bound to the hydrophobic pocket at the distal heme cavity and were oxidized efficiently by compound I (k3), which has a one-electron reduction potential of 1.35 V. By contrast, compound II (E degrees ' of the compound II/ferric couple is 0.97 V) reduction (k4) was extremely slow. As a consequence compound II, which does not participate in the halogenation cycle, accumulated. The extent of chlorinating activity inhibition (IC50) was related to the k3/k4 ratio. The most efficient inhibitors were 5-fluorotryptamine and 5-chlorotryptamine with IC50 of 0.79 microM and 0.73 microM and k3/k4 ratios of 386,000 and 224,000, respectively. The reversible mechanism of inhibition is discussed with respect to the enzymology of MPO and the development of drugs against HOCl-dependent tissue damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794935     DOI: 10.1016/j.bcp.2005.02.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Authors:  Irina I Vlasova; Wei-Hong Feng; Julie P Goff; Angela Giorgianni; Duc Do; Susanne M Gollin; Dale W Lewis; Valerian E Kagan; Jack C Yalowich
Journal:  Mol Pharmacol       Date:  2010-11-19       Impact factor: 4.436

2.  2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation.

Authors:  Anna-Karin Tidén; Tove Sjögren; Mats Svensson; Alexandra Bernlind; Revathy Senthilmohan; Francoise Auchère; Henrietta Norman; Per-Olof Markgren; Susanne Gustavsson; Staffan Schmidt; Stefan Lundquist; Louisa V Forbes; Nicholas J Magon; Louise N Paton; Guy N L Jameson; Håkan Eriksson; Anthony J Kettle
Journal:  J Biol Chem       Date:  2011-08-31       Impact factor: 5.157

3.  Inhibition of Myeloperoxidase.

Authors:  Jala Soubhye; Paul G Furtmüller; Francois Dufrasne; Christian Obinger
Journal:  Handb Exp Pharmacol       Date:  2021

4.  Thioxo-dihydroquinazolin-one Compounds as Novel Inhibitors of Myeloperoxidase.

Authors:  Yang Li; Thota Ganesh; Becky A Diebold; Yerun Zhu; James W McCoy; Susan M E Smith; Aiming Sun; J David Lambeth
Journal:  ACS Med Chem Lett       Date:  2015-08-31       Impact factor: 4.345

5.  Cyanidin-3-glucoside inhibits UVB-induced oxidative damage and inflammation by regulating MAP kinase and NF-κB signaling pathways in SKH-1 hairless mice skin.

Authors:  Poyil Pratheeshkumar; Young-Ok Son; Xin Wang; Sasidharan Padmaja Divya; Binoy Joseph; John Andrew Hitron; Lei Wang; Donghern Kim; Yuanqin Yin; Ram Vinod Roy; Jian Lu; Zhuo Zhang; Yitao Wang; Xianglin Shi
Journal:  Toxicol Appl Pharmacol       Date:  2014-07-22       Impact factor: 4.219

6.  Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates.

Authors:  Louisa V Forbes; Tove Sjögren; Françoise Auchère; David W Jenkins; Bob Thong; David Laughton; Paul Hemsley; Garry Pairaudeau; Rufus Turner; Håkan Eriksson; John F Unitt; Anthony J Kettle
Journal:  J Biol Chem       Date:  2013-11-05       Impact factor: 5.157

Review 7.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

8.  Ceruloplasmin is an endogenous inhibitor of myeloperoxidase.

Authors:  Anna L P Chapman; Tessa J Mocatta; Sruti Shiva; Antonia Seidel; Brian Chen; Irada Khalilova; Martina E Paumann-Page; Guy N L Jameson; Christine C Winterbourn; Anthony J Kettle
Journal:  J Biol Chem       Date:  2013-01-10       Impact factor: 5.157

9.  Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention.

Authors:  Michael J Davies
Journal:  J Clin Biochem Nutr       Date:  2010-12-28       Impact factor: 3.114

10.  ESR and X-ray Structure Investigations on the Binding and Mechanism of Inhibition of the Native State of Myeloperoxidase with Low Molecular Weight Fragments.

Authors:  Balagopalakrishna Chavali; Thierry Masquelin; Mark J Nilges; David E Timm; Stephanie L Stout; William F Matter; Najia Jin; Prabhakar K Jadhav; Gary G Deng
Journal:  Appl Magn Reson       Date:  2015-05-19       Impact factor: 0.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.